ArticleJournal of the ASEAN Federation of Endocrine Societies2026
Hirata's Disease: A Case Report.
Article in Journal of the ASEAN Federation of Endocrine Societies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Insulin Autoimmune Syndrome (IAS), also known as Hirata's disease, is a rare endocrine disorder characterized by recurrent hypoglycemia due to endogenous hyperinsulinemia and the presence of insulin autoantibodies (IAAs). We report a case of IAS successfully treated with corticosteroid therapy. Notably, the definitive diagnosis was established only during the second hospitalization, after multiple recurrent hypoglycemic episodes. The delayed diagnosis reflects the nonspecific presentation and the low initial suspicion for autoimmune hypoglycemia. In the first admission, although insulinoma had been excluded, the patient was discharged without a confirmed diagnosis. This case highlights the importance of early insulin autoantibody testing in patients with unexplained endogenous hyperinsulinemic hypoglycemia to prevent diagnostic delay and unnecessary investigations. Initial evaluation prioritized exclusion of insulinoma, the most common cause of endogenous hyperinsulinemic hypoglycemia, before autoimmune testing was pursued.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.